Xenon Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
On September 27, 2024, Ian Mortimer, the Company’s President and Chief Executive Officer and a member of the Board of Directors, adopted a trading plan intended to satisfy the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The plan provides that commencing January 7, 2025, Mr. Mortimer may sell up to an aggregate of 630,302 of the Company’s common shares,605,000 of which are shares to be acquired upon the exercise of stock options. The plan terminates on the earlier of the date all shares under the trading plan are sold or June 30, 2026.
The number of shares to be sold in accordance with this trading plan is subject to various minimum price targets, or limit prices, being met on each applicable predetermined sale date. In the event the minimum price targets are not met on the applicable predetermined sale date or on any subsequent predetermined sale date, the corresponding shares shall not be sold.
-61-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.